Market Overview

Heat Biologics Cools Off, Bluebird Bio Heats Up

Heat Biologics Cools Off, Bluebird Bio Heats Up
Related BLUE
The Companies That Led 2017's Biotech Rally
3 Biotech Pipeline Areas To Keep An Eye On In 2018
Can Litecoin Continue Its Run In 2018? (Seeking Alpha)
Related CELG
Key Takeaways From The J.P. Morgan Healthcare Conference
Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making
Investment Ideas In Quality Stocks (Seeking Alpha)

In a classic example of how trial results can impact stock prices, shares of Heat Biologics Inc (NASDAQ: HTBX) plunged 58 percent in the Thursday’s pre-market hours following a negative outcome of its bladder cancer study, while bluebird bio Inc (NASDAQ: BLUE)’s impressive early cancer studies propelled the stock by 22 percent.

The Trials

Heat Biologics said its phase 2 trial of Vesigenurtacel-L (HS-410) in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC) failed to meet primary endpoint. The primary endpoint was proportion of recurrence-free survival at one year between the vaccine and placebo arms of the trial.

the other hand, bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed objective anti-tumor responses in heavily pre-treated multiple myeloma patients. bluebird bio is developing bb2121 in collaboration with Celgene Corporation (NASDAQ: CELG).

Recent Stock Performance

Shares of Durham, North Carolina-based Heat Biologics closed Wednesday’s trading at $2.87, while bluebird bio ended trading at $60.35.

In the pre-market hours Thursday, Heat Biologics sank 58 percent to $1.20, while Cambridge, Massachusetts-based bluebird bio surged 22.54 percent to $73.95. Shares of Celegene too gained 1.6 percent to $120.45 on the news.

Posted-In: bb2121Biotech News Health Care FDA Movers Trading Ideas General Best of Benzinga


Related Articles (CELG + BLUE)

View Comments and Join the Discussion!